Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Recap by typeshit. Post by Facebook on Facebook.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
The analysis points to CagriSema filings, a DKK 15b buyback and Wegovy pill capacity, while flagging margin pressure and flat 2026 guidance as risks.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Loading…